老虎證券

BRIEF-Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Reuters
03-27
BRIEF-Savara Completes Submission Of The Biologics License Application <a href="https://laohu8.com/S/BLA.AU">$(BLA.AU)$</a> To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

March 26 (Reuters) - Savara Inc SVRA.O:

  • SAVARA COMPLETES SUBMISSION OF THE BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR MOLBREEVI* AS A TREATMENT FOR AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

  • SAVARA INC - TO SUBMIT MOLBREEVI MAA IN EUROPE BY END OF 2025

  • SAVARA INC: COMMERCIAL PREPARATIONS ARE ON-TRACK TO SUPPORT A POTENTIAL LAUNCH IN EARLY 2026

Source text: ID:nBw6ZdRW0a

Further company coverage: SVRA.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10